HC Wainwright Reiterates “Buy” Rating for enGene (NASDAQ:ENGN)

enGene (NASDAQ:ENGN)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $25.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 377.10% from the stock’s previous close.

ENGN has been the topic of a number of other research reports. Raymond James started coverage on enGene in a research note on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 target price on the stock. Citizens Jmp upgraded enGene to a “strong-buy” rating in a research report on Monday, November 18th. Piper Sandler assumed coverage on enGene in a research report on Tuesday, February 18th. They set an “overweight” rating and a $26.00 price objective for the company. UBS Group lowered shares of enGene from a “buy” rating to a “neutral” rating and reduced their target price for the company from $34.00 to $7.00 in a report on Friday, February 14th. Finally, JMP Securities reiterated a “market outperform” rating and set a $18.00 price target on shares of enGene in a report on Monday, December 23rd. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, enGene presently has an average rating of “Buy” and a consensus price target of $25.89.

enGene Stock Down 0.2 %

enGene stock opened at $5.24 on Tuesday. enGene has a fifty-two week low of $4.42 and a fifty-two week high of $18.40. The firm has a market capitalization of $267.12 million, a price-to-earnings ratio of -9.03 and a beta of -0.61. The stock’s fifty day moving average is $6.65 and its two-hundred day moving average is $7.16. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. Analysts predict that enGene will post -1.56 EPS for the current fiscal year.

Hedge Funds Weigh In On enGene

Hedge funds have recently made changes to their positions in the stock. Deep Track Capital LP grew its holdings in shares of enGene by 74.8% during the 4th quarter. Deep Track Capital LP now owns 4,557,575 shares of the company’s stock worth $30,308,000 after purchasing an additional 1,949,942 shares during the period. VR Adviser LLC lifted its position in enGene by 41.5% during the fourth quarter. VR Adviser LLC now owns 5,046,414 shares of the company’s stock valued at $33,559,000 after buying an additional 1,480,573 shares in the last quarter. Fcpm Iii Services B.V. grew its stake in enGene by 11.0% during the fourth quarter. Fcpm Iii Services B.V. now owns 9,632,561 shares of the company’s stock worth $64,057,000 after buying an additional 954,610 shares during the period. Orbimed Advisors LLC acquired a new stake in shares of enGene in the fourth quarter worth $6,120,000. Finally, Point72 Asset Management L.P. raised its stake in shares of enGene by 1,410.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after acquiring an additional 619,100 shares during the period. Institutional investors and hedge funds own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.